Daily Ards Research Analysis
Three studies advance ARDS science across bedside care and mechanisms: a cohort links prolonged ECMO duration and age to high pressure injury incidence in COVID‑19 ARDS; a preclinical study shows the mitochondrial peptide SS‑31 mitigates neonatal ARDS via TXNIP/NLRP3 modulation; and Mendelian randomization plus mouse data support HGF/c‑Met activation (via luteolin) as protective in ALI/ARDS.
Summary
Three studies advance ARDS science across bedside care and mechanisms: a cohort links prolonged ECMO duration and age to high pressure injury incidence in COVID‑19 ARDS; a preclinical study shows the mitochondrial peptide SS‑31 mitigates neonatal ARDS via TXNIP/NLRP3 modulation; and Mendelian randomization plus mouse data support HGF/c‑Met activation (via luteolin) as protective in ALI/ARDS.
Research Themes
- ECMO care quality and pressure injury prevention in ARDS
- Mitochondrial and inflammasome-targeted therapy (TXNIP/NLRP3) in neonatal ARDS
- HGF/c-Met pathway activation and natural compounds (luteolin) in ALI/ARDS
Selected Articles
1. Szeto-Schiller 31 eases acute lung injury in neonatal mice with acute respiratory distress syndrome by mediating TXNIP expression and NLRP3 inflammasome activation.
In neonatal ARDS models, SS‑31 reduced oxidative stress, apoptosis, vascular leakage, and inflammation, improving lung histology and barrier integrity. Human neonatal serum profiling showed elevated TXNIP/NLRP3 pathway markers that were suppressed by SS‑31 in preclinical systems, supporting TXNIP/NLRP3 as a target.
Impact: Identifies a mitochondria-inflammasome axis (TXNIP/NLRP3) as a modifiable driver in neonatal ARDS and demonstrates a candidate therapeutic (SS‑31) across in vitro and in vivo models.
Clinical Implications: While not yet ready for clinical use, SS‑31 and TXNIP/NLRP3 modulation may inform future neonatal ARDS trials and biomarker-driven stratification.
Key Findings
- SS‑31 reduced LPS‑induced oxidative stress, apoptosis, vascular permeability, and inflammatory responses in HLMVECs.
- SS‑31 improved histopathology and edema with better alveolar‑capillary barrier integrity in neonatal ARDS mice.
- TXNIP, NLRP3, caspase‑1, and ASC were elevated in newborns with ARDS; SS‑31 suppressed TXNIP and NLRP3 in preclinical models.
Methodological Strengths
- Integrated in vitro HLMVEC assays and in vivo neonatal mouse ARDS model
- Human neonatal serum biomarker assessment aligning with mechanistic pathway
Limitations
- Preclinical study without human interventional data
- Sample sizes and dosing/safety profiles not detailed for clinical translation
Future Directions: Dose-finding, pharmacokinetics/safety, and early‑phase trials of SS‑31 in neonatal ARDS; validation of TXNIP/NLRP3 biomarkers for patient stratification.
BACKGROUND: Mitochondrial-targeting anti-oxidant Szeto-Schiller 31 (SS-31) can ease lung injury in several diseases, but whether SS-31 can ameliorate acute lung injury (ALI) in neonatal acute respiratory distress syndrome (ARDS) is unclear. The objective of this study is to explore the efficacy of SS-31 against ALI and the associated molecular mechanisms. METHODS: Thioredoxin-interacting protein (TXNIP) was found to be a hub gene for ARDS by bioinformatics analysis. Using the Search Tool for Interactions of Chemicals (STITCH) database, SS-31 was found to work via mediating TXNIP expression. Serum levels of some parameters were analyzed by enzyme-linked immunosorbent assay (ELISA). The effect of SS-31 on oxidative stress (OxS) injury, inflammation, apoptosis, and vascular permeability in lipopolysaccharide (LPS)-induced human lung microvascular epithelial cells (HLMVECs) and ARDS mouse models were investigated to assess the efficiency of SS-31 on ALI by a series of experiments [5-ethynyl-2'-deoxyuridine (EDU), lactate dehydrogenase (LDH), western blot, flow cytometry, histopathological analysis, wet-to-dry weight ratio, and so on]. RESULTS: SS-31 treatment mitigated LPS-induced OxS, apoptosis, vascular permeability, and inflammatory response in HLMVECs. Consistently, SS-31 treatment ameliorated histopathological changes and oedema in the lungs of neonatal ARDS mice, accompanied by improved alveolar capillary barrier integrity as well as reduced OxS, inflammation, and apoptosis. Serum TXNIP, caspase-1, apoptosis-associated speck-like protein (ASC), and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) levels were overtly higher in newborns with ARDS, and a positive correlation was observed between TXNIP and NLRP3. Interestingly, SS-31 treatment repressed TXNIP and NLRP3 protein levels in ARDS cells and animal models. CONCLUSIONS: SS-31 may repress OxS, inflammatory response, apoptosis, and vascular permeability by targeting the TXNIP/NLRP3 pathway in neonatal ARDS, thereby ameliorating ALI.
2. Luteolin attenuates inflammation and apoptosis in LPS-induced ALI mice by activating the HGF/c-Met pathway.
Two-sample MR suggests higher HGF causally reduces ARDS risk (OR 0.326), and experimental validation shows luteolin activates HGF/c‑Met signaling to decrease lung inflammation and apoptosis in LPS‑induced ALI mice.
Impact: Combines human genetic inference (MR) with preclinical validation to nominate HGF/c‑Met activation—achievable by luteolin—as a potential ARDS-modifying strategy.
Clinical Implications: Supports exploration of HGF agonism or c‑Met activation strategies, including nutraceutical candidates, in early-phase ARDS studies; translational work is needed before clinical adoption.
Key Findings
- MR analysis indicated a causal protective effect of HGF on ARDS risk (IVW β = -1.120, OR = 0.326, 95% CI 0.116–0.916, P = 0.033).
- Network pharmacology highlighted luteolin as an active ingredient linked to HGF upregulation.
- In LPS-induced ALI mice, luteolin reduced lung inflammation and apoptosis via HGF/c‑Met pathway activation.
Methodological Strengths
- Two-sample Mendelian randomization to infer causality
- Preclinical validation linking mechanism (HGF/c‑Met) to phenotypic improvement
Limitations
- MR significance is modest and depends on instrument strength and assumptions
- Mouse model and network pharmacology limit immediate clinical generalizability
Future Directions: Validate HGF/c‑Met activation in diverse ARDS models, assess dosing and safety of luteolin or HGF agonists, and consider biomarker‑guided early clinical trials.
OBJECTIVE: To investigate the protective effects of luteolin on ALI induced by lipopolysaccharide (LPS) in male mice and to explore the underlying mechanisms. METHODS: A two-sample Mendelian randomization (MR) analysis was conducted to assess the causal relationship between hepatocyte growth factor (HGF) and acute respiratory distress syndrome (ARDS). Network pharmacology analysis was employed to identify herbs that mitigate inflammation and apoptosis by upregulating HGF expression and to determine the hub active ingredients. These findings were subsequently validated through RESULTS: The MR analysis demonstrated a causal effect of HGF on ARDS (IVW: β = -1.120, OR = 0.326, 95% CI = 0.116-0.916, P = 0.033). Among herbs associated with upregulating HGF expression, CONCLUSION: Luteolin attenuates inflammation and apoptosis in the lungs of LPS-induced ALI mice via activation of the HGF/c-Met pathway.
3. Pressure injuries in patients receiving extracorporeal membrane oxygenation: a tertiary centre experience.
In 78 COVID‑19 ARDS patients on VV‑ECMO, 30.8% had existing pressure injuries on ICU arrival and 44.4% developed new injuries (mostly stage 2) during prolonged ECMO (median 48.5 days), with median time to PI of 21 days. Older age and longer ECMO duration independently predicted PI development.
Impact: Quantifies PI burden and identifies modifiable exposure (ECMO duration) and patient risk (age) in ARDS on ECMO, informing prevention bundles.
Clinical Implications: Implement rigorous PI prevention bundles (repositioning, offloading, device padding, moisture control) and heightened surveillance, especially in older patients and those on prolonged ECMO.
Key Findings
- Baseline PI present in 24/78 (30.8%) patients upon ICU admission on ECMO.
- New PIs occurred in 24/54 (44.4%) during ECMO; majority were stage 2 (55%).
- Median time to new PI was 21 days; age (OR 1.103) and ECMO duration (OR 1.048) independently predicted PI development.
Methodological Strengths
- Cohort design with multivariable analysis to identify independent predictors
- Clear operational definitions and clinically relevant outcomes
Limitations
- Single-center retrospective design with COVID-19 era case-mix
- High mortality may confound PI risk and competing outcomes
Future Directions: Prospective multicenter validation; test targeted PI prevention bundles and device innovations in ECMO populations.
OBJECTIVE: Pressure injuries (PIs) are common in patients receiving intensive care and extracorporeal membrane oxygenation (ECMO). This study assessed the incidence and risk factors of PIs in patients receiving ECMO for COVID-19-associated acute respiratory distress syndrome (ARDS). METHOD: Patients who were admitted to the intensive care unit (ICU) with severe COVID-19-associated ARDS and received veno-venous ECMO between April 2020 and January 2022 were evaluated. All patients were monitored, evaluated and managed according to the RESULTS: A total of 78 patients (median age 45 years) received ICU care and ECMO support. Of these, 75 patients were transferred to the ICU while on ECMO support; 24/78 (30.8%) patients already had PIs. New PIs developed in 24 patients (24/54, 44.4%) during prolonged periods of ECMO (median 48.5 days). The new PIs were mainly stage 2 (55%). The median time to new PI development during ECMO was 21 (range 4-60) days. The mortality rate was 32/54 (59.3%). In multivariable analysis, age (odds ratio (OR): 1.103, 95% confidence interval (CI): 1.022, 1.191; p=0.027) and ECMO duration (OR: 1.048, 95% CI: 1.016, 1.081; p=0.003) were independent predictors of PI development. CONCLUSION: Strict compliance with the clinical practice guidelines for PIs by a dedicated ICU team may considerably reduce the incidence of PIs among patients receiving ECMO for prolonged periods.